SeDeM as a Tool to Validate Drug Substance Manufacturing Processes and Assess Scalability and Suitability for Direct Compression: Supplier Screening

Author:

Figuera-Figuera Alba1,Suñé-Pou Marc12ORCID,Pérez-Lozano Pilar12ORCID,García-Montoya Encarna12ORCID,Amela-Navarro Joaquim1,Suñé-Negre Josep M.12

Affiliation:

1. Pharmaceutical Technology and Physico-Chemical Department, Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain

2. IDIBELL-UB Research Group, Pharmacotherapy, Pharmacogenomics and Pharmaceutical Technology, Avinguda Granvia, 199-203, 08908 L’Hospitalet de Llobregat, Spain

Abstract

During the development of an oral solid form of a drug substance, a thorough understanding of the critical material attributes is necessary, as the physical properties of the active pharmaceutical ingredient (API) can profoundly influence the drug product’s manufacturability, critical quality attributes, and bioavailability. The objective of this study was to validate the manufacturing process of the drug Linezolid from three different sources at both the pilot and industrial scale and to identify differences in critical material attributes between the API manufacturers. Furthermore, the scalability factor between the pilot and industrial scale and the suitability of a process for direct compression were also evaluated. In the present study, the different sources of API were characterized by SeDeM methodology, particle size distribution, and scanning electron microscopy determinations. The statistical analysis revealed that no statistically significant differences were found for any of the parameters under study for the same API source analyzed on both scales. On the other hand, for most of the parameters evaluated, statistical differences were observed between the different sources. It was concluded that SeDeM was able to successfully validate the API manufacturing process, assess scalability, and distinguish between sources. Therefore, it could be highly valuable in the formulation phase to select the best API source.

Publisher

MDPI AG

Subject

Pharmaceutical Science

Reference63 articles.

1. Understanding Pharmaceutical Quality by Design;Yu;AAPS J.,2014

2. Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control;Yu;Pharm. Res.,2008

3. European Medicines Agency (2009). ICH Topic Q 8 (R2) Pharmaceutical Development, Step 5: Note for Guidance on Pharmaceutical Development, EMA.

4. European Medicines Agency (2012). ICH Q11 on Development and Manufacture of Drug Substances, EMA.

5. Schlindwein, W., and Gibson, M. (2017). Pharmaceutical Quality by Design: A Practical Approach, John Wiley & Sons Ltd.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3